• Ensysce Biosciences cautioned that observations from a small, uncontrolled psilocybin pilot should not be interpreted as evidence of efficacy for its CRPS treatment program.
• Participants received a formulation supplied under Oregon’s psilocybin program, not its CY200 drug candidate.
• No participants have enrolled in the planned UK Phase 2 trial of CY200 for CRPS Type 1.
• The clinical trial application was submitted on September 11, 2026, with a regulatory decision expected in early December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047317), on October 16, 2026, and is solely responsible for the information contained therein.